GSK plc (LON:GSK) Receives Average Recommendation of “Moderate Buy” from Brokerages

GSK plc (LON:GSK) has earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is GBX 1,842.50 ($23.89).

Several equities research analysts have recently issued reports on GSK shares. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Monday, July 29th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,820 ($23.60) price objective on shares of GSK in a research note on Tuesday, September 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,850 ($23.99) target price on shares of GSK in a research note on Tuesday, September 3rd. Citigroup decreased their price target on GSK from GBX 2,120 ($27.49) to GBX 1,900 ($24.64) and set a “buy” rating for the company in a research note on Friday, July 5th. Finally, Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Wednesday, August 28th.

GSK Stock Performance

LON:GSK opened at GBX 1,407 ($18.25) on Thursday. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. The stock’s fifty day moving average is GBX 1,549.30 and its 200 day moving average is GBX 1,596.52. The firm has a market capitalization of £57.41 billion, a PE ratio of 1,245.13, a PEG ratio of 1.24 and a beta of 0.31. GSK has a fifty-two week low of GBX 1,371.40 ($17.78) and a fifty-two week high of GBX 1,823.50 ($23.65).

GSK Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date is Thursday, November 14th. This represents a yield of 1.03%. GSK’s payout ratio is currently 5,309.73%.

Insiders Place Their Bets

In other GSK news, insider Elizabeth (Liz) McKee Anderson bought 446 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were acquired at an average price of GBX 2,051 ($26.60) per share, with a total value of £9,147.46 ($11,862.87). In related news, insider Jonathan Symonds acquired 7,150 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($18.08) per share, for a total transaction of £99,671 ($129,258.20). Also, insider Elizabeth (Liz) McKee Anderson purchased 446 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were purchased at an average cost of GBX 2,051 ($26.60) per share, with a total value of £9,147.46 ($11,862.87). In the last ninety days, insiders bought 7,604 shares of company stock worth $10,893,886. 1.61% of the stock is currently owned by company insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.